TARGETED ANTI-CANCER THERAPIES, IMMUNOTHERAPY AND DRUG DELIVERY

WORLD CONGRESS 2017

5 - 7 OCTOBER 2017 | CITY CONVENTION CENTRE

REGISTER BY 7 SEPTEMBER 2017 TO SAVE UP TO AU$100!

SUPPORTING PARTNERS

KEY THEMES

Immunotherapies
- CAR T Cell Therapy
- NK Cell Cancer Therapy
- Immune Checkpoint Inhibitors

Tumor Vaccinology

Cancer Genome
- Gene Mutations

Integrative Oncology
- Functional Pathology

Precision Medicine
- Biomarkers

Nanotechnology in Cancer
- Nanotheranostics
- Nanoknife

CRISPR
- Killing Cancer Cells with Genome Editing

Targeted Anti-Cancer Therapy & Drug Delivery
- Signal Transduction Therapies
- Angiogenesis Inhibitors
- Apoptosis Inducers
- Hormone Therapies

Soft Robotics Drug Delivery

Stem Cell Therapy
- The Revolutionary & Regenerative Treatment for Cancer

Call: +61 3 9909 7310 | Email: admissions@claridenglobal.com | Visit: http://www.claridenglobal.com

DermNet New Zealand

All about the skin
TARGETED ANTI-CANCER THERAPIES, IMMUNOTHERAPY AND DRUG DELIVERY
WORLD CONGRESS 2017

MAIN CONGRESS: 6 – 7 OCTOBER 2017
PRE CONGRESS SITE VISIT AND WORKSHOP: 5 OCTOBER 2017
VENUE: CITY CONVENTION CENTRE

THE CONGRESS AT A GLANCE

DAY 1: FRIDAY, 6 OCTOBER 2017

• Keynote Session: Understanding the Biochemical Basis of Cytotoxic Mechanism of NK Cells and T Lymphocytes
• Immunotherapy 2.0: Advancing Cancer Treatment with IDO1 Inhibitors
• Survival Results from CheckMate 067 - Phase III Trial with Advanced Melanoma Patients
• Gene Mutations & Signalling Pathways
• An Introduction of Precision Medicine
• Targeting CML & High-Grade Serous Ovarian Cancer

DAY 2: SATURDAY, 7 OCTOBER 2017

• Keynote Session: Nanotheranostics for Cancer Management
• Breakthrough in using Soft Robotics Devices for Drug Delivery
• Nanoknife, the Irreversible Electroporation
• A Novel Therapeutic Approach to Cell Death: Apoptosis Inducers CRISPR: Killing Cancer Cells with Genome Editing: CRISPR-Cas-9
• Stem Cell Therapy: The Revolutionary & Regenerative Treatment for Cancer
• Integrative Oncology
• Endocrine Disruptors & Environmental Toxicants in Cancer

PRE CONGRESS SITE VISIT & WORKSHOP: THURSDAY, 5 OCTOBER 2017

• Workshop: Improving Survivorship Services by Providing Comprehensive Cancer Care to Cancer Survivors
• Workshop: Advocating Personalized Medicine with Palliative Care

KEY TAKEAWAYS FROM THE TARGETED ANTI-CANCER THERAPIES, IMMUNOTHERAPY & DRUG DELIVERY WORLD CONGRESS 2017

1. Catch up with the latest and groundbreaking medical findings in cancer management
2. Uncover promising frontier and life-changing medical research in suppressing, inhibiting and relieving suffering of cancer patients
3. Revolutionize cancer care with the augmentation of technology
4. Edge towards potential cancer cures by learning from renowned experts who created milestones in cancer care
5. Strengthen partnerships between the public and private sector in the field of sciences, medical and pharmaceutical in the impetus search for novel therapeutic cancer treatments

All delegates are also invited to join us at our Champagne Networking Session. Enjoy a perfect glass of champagne, build exclusive networks and exchange powerful insights with delegates.

FEATURED SPEAKERS

A/Prof Marcel Dinger
Head, Kinghorn Centre for Clinical Genomics, Lab Head: Genome Informatics
Garvan Institute of Medical Research

A/Prof Ching Lai Ming
Professor and Head: Stromal Targeting Agents Group
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, New Zealand

An Introduction to Precision Medicine: Translation of Technology from Research into the Clinic

Dr Nicholas Huntington
Lab Head: Molecular Immunology
Walter & Eliza Hall Institute of Medical Research (WEHI)

Exploring the Minimally Invasive Option for Cancer Treatment - Nanoknife, the Irreversible Electroporation

Dr Huynh The Hung
Principal Investigator: Lab of Molecular Endocrinology, Division of Cellular & Molecular Research
National Cancer Centre Singapore (NCCS)

A/Prof Tan Meng How
Senior Research Scientist of Stem Cell & Regenerative Biology
Genome Institute of Singapore (GIS)
Assistant Professor: School of Chemical and Biomedical Engineering
Nanyang Technological University (NTU)

Targeting Fibroblast Growth Factor Signalling Pathway in Hepatocellular Carcinoma (HCC)

CRISPR: Killing Cancer Cells with Genome Editing

All delegates are also invited to join us at our Champagne Networking Session. Enjoy a perfect glass of champagne, build exclusive networks and exchange powerful insights with delegates.

Call: +61 3 9909 7310 | Email: admissions@claridenglobal.com | Visit: http://www.claridenglobal.com
Meet the Incredible Lineup of Speakers

5 - 7 OCTOBER 2017 | CITY CONVENTION CENTRE

With key experts from across industry including:

**An Introduction to Precision Medicine: Translation of Technology from Research into the Clinic**

- **A/Prof Marcel Dinger**
  Head, Kinghorn Centre for Clinical Genomics, Lab Head: Genome Informatics
  Garvan Institute of Medical Research

- **A/Prof Ching Lai Ming**
  Professor and Head: Stromal Targeting Agents Group
  Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, University of Auckland, New Zealand

- **Dr Huynh The Hung**
  Principal Investigator: Lab of Molecular Endocrinology, Division of Cellular & Molecular Research
  National Cancer Centre Singapore (NCCS)

**NK (Natural Killer) Cell Cancer Immunotherapies**

- **Dr Nicholas Huntington**
  Lab Head: Molecular Immunology
  Walter Eliza Hall Institute of Medical Research (WEHI)

- **Dr Helen Kamoudias**
  Head of the Radiology Research Unit
  The Alfred Hospital

- **Dr Matt Dun**
  Group Leader: Molecular Oncology Group Hunter Medical Research Institute (HMRI)

**CRISPR: Killing Cancer Cells with Genome Editing**

- **Prof Stephen J Clarke**
  Director, Area Cancer Services; Professor of Medicine
  Northern Sydney Local Health District; University of Sydney

- **Dr Huynh The Hung**
  Principal Investigator: Lab of Molecular Endocrinology, Division of Cellular & Molecular Research
  National Cancer Centre Singapore (NCCS)

**The Use of Inflammatory Markers to Predict Cancer**

- **A/Prof Tan Meng How**
  Senior Research Scientist of Stem Cell & Regenerative Biology
  Genome Institute of Singapore (GIS)
  Assistant Professor: School of Chemical and Biomedical Engineering
  Nanyang Technological University (NTU)

- **Dr Paul A Beavis**
  Chief Investigator, Immunotherapy Program
  Peter MacCallum Cancer Centre

- **Dr Peter Hersey**
  Honorary Professor in Immuno Oncology
  Centenary Institute, University of Sydney

**Understanding the Biochemical Basis of Cytotoxic Mechanism of NK Cells and T Lymphocytes**

- **Dr Lev Kats**
  Team Leader, Cancer Therapeutic Program
  Peter MacCallum Cancer Centre

- **Dr Paul A Beavis**
  Chief Investigator, Immunotherapy Program
  Peter MacCallum Cancer Centre

- **Dr Peter Hersey**
  Honorary Professor in Immuno Oncology
  Centenary Institute, University of Sydney

**Targeting the Epigenome in Acute Myeloid Leukemia (AML)**

- **A/Prof Tan Meng How**
  Senior Research Scientist of Stem Cell & Regenerative Biology
  Genome Institute of Singapore (GIS)
  Assistant Professor: School of Chemical and Biomedical Engineering
  Nanyang Technological University (NTU)

- **Dr Lev Kats**
  Team Leader, Cancer Therapeutic Program
  Peter MacCallum Cancer Centre

- **Dr Peter Hersey**
  Honorary Professor in Immuno Oncology
  Centenary Institute, University of Sydney

**Exploring the Minimally Invasive Option for Cancer Treatment – Nanoknife, the Irreversible Electroapertion**

- **A/Prof Marcel Dinger**
  Head, Kinghorn Centre for Clinical Genomics, Lab Head: Genome Informatics
  Garvan Institute of Medical Research

- **Dr Helen Kamoudias**
  Head of the Radiology Research Unit
  The Alfred Hospital

- **A/Prof Tan Meng How**
  Senior Research Scientist of Stem Cell & Regenerative Biology
  Genome Institute of Singapore (GIS)
  Assistant Professor: School of Chemical and Biomedical Engineering
  Nanyang Technological University (NTU)

**Targeting the Epigenome in Acute Myeloid Leukemia (AML)**

- **A/Prof Tan Meng How**
  Senior Research Scientist of Stem Cell & Regenerative Biology
  Genome Institute of Singapore (GIS)
  Assistant Professor: School of Chemical and Biomedical Engineering
  Nanyang Technological University (NTU)

- **Dr Lev Kats**
  Team Leader, Cancer Therapeutic Program
  Peter MacCallum Cancer Centre

- **Dr Peter Hersey**
  Honorary Professor in Immuno Oncology
  Centenary Institute, University of Sydney

**Augmenting CAR T Cell Function for Application in Solid Cancer**

- **A/Prof Tan Meng How**
  Senior Research Scientist of Stem Cell & Regenerative Biology
  Genome Institute of Singapore (GIS)
  Assistant Professor: School of Chemical and Biomedical Engineering
  Nanyang Technological University (NTU)

- **Dr Lev Kats**
  Team Leader, Cancer Therapeutic Program
  Peter MacCallum Cancer Centre

- **Dr Peter Hersey**
  Honorary Professor in Immuno Oncology
  Centenary Institute, University of Sydney

**Survival Results from a Phase III Trial of Nivolumab Combined with Ipilimumab in Treatment-naïve Patients with Advanced Melanoma (CheckMate 067)**

- **Call: +61 3 9909 7310 | Email: admissions@claridenglobal.com | Visit: http://www.claridenglobal.com**
Meet the Incredible Lineup of Speakers

5 - 7 OCTOBER 2017 | CITY CONVENTION CENTRE

Dr Prashant Sawant
Chief Scientist
Intraceuticals
Nanotheranostics for Cancer Management

Dr Elaine Sanij
Senior Scientist: Cancer Signalling Laboratory, Oncogenic Signalling and Growth Control Programme
Peter MacCallum Cancer Centre
Activation of Nucleolar DNA Damage Signalling by CX-5461 is a Novel Therapeutic Strategy for High-Grade Serous Ovarian Cancer

Dr Abbas Shafiee
Postdoctoral Research Fellow, Institute of Health and Biomedical Innovation
Queensland University of Technology
Stem Cell Therapy: The Revolutionary & Regenerative Treatment for Cancer

Vanita Dahlia
Integrative Medicine Practitioner & Functional Pathology Clinical Consultant
Nutripath
Endocrine Disruptors and Environmental Toxicants in Cancer

Dr Ruth Kluck
Lab Head: Molecular Genetics of Cancer Division
Walter + Eliza Hall Institute of Medical Research (WEHI)
Exploring intracellular antibodies as a novel approach to directly trigger Bak-mediated apoptosis

Exploring intracellular antibodies as a novel approach to directly trigger Bak-mediated apoptosis
Exploring intracellular antibodies as a novel approach to directly trigger Bak-mediated apoptosis

Call: +61 3 9909 7310 | Email: admissions@claridenglobal.com | Visit: http://www.claridenglobal.com
Welcome to the
TARGETED ANTI-CANCER THERAPIES, IMMUNOTHERAPY & DRUG DELIVERY WORLD CONGRESS 2017

5 - 7 OCTOBER 2017 | CITY CONVENTION CENTRE

Dear Colleagues,

The War on Cancer has long been waged dated back to the 1970s with the aim of eradicating cancer from earth. Close to 50 years have passed, yet, the cure for cancer remains elusive, distant and unobtainable. It baffles us how that despite advancement in human race conquering outer space, creating artificial intelligence, turning the once-big-bulky supercomputers into the size of our palm, as well as cloning human embryo; cancer, the very cells within our body remains incurable.

With 1 in 2 Australians expected to be affected by cancer by the age of 85, research breakthroughs are urgently needed. This 5 - 7 October 2017, Clariden Global welcomes you to the Targeted Anti-Cancer Therapies, Immunotherapy & Drug Delivery World Congress 2017 in Melbourne, Australia, a global gathering of oncologists, scientists, physicians, researchers and pharmacists all across the four corners of the world. The congregation of healthcare experts and thought leaders aims to bring together various stakeholders in the medical and healthcare ecosystem for an exchange of scientific clinical research findings, ideas and best practices in cancer management. This event is carefully researched and crafted with the most desired insights in the oncology industry featuring trending information, challenging issues and insightful keynote sessions that will aid you in the impetus search for more effective cancer treatments.

Mark 5-7 October 2017 in your calendar and book your seat now! We welcome you to tap into the expertise of our panel of oncologists, scientists and researchers to discover the latest developments in new cancer diagnostics, therapies, preventive measures and early detection methods evidenced by case studies, clinical as well as translational researches. Join us in the relentless and unflinching commitment to finding a cure for cancer! We look forward to welcoming you this October!

Best Regards,

Shermaine Ong
Conference Director

Call: +61 3 9909 7310 | Email: admissions@claridenglobal.com | Visit: http://www.claridenglobal.com
Welcome to the
TARGETED ANTI-CANCER THERAPIES, IMMUNOTHERAPY & DRUG DELIVERY WORLD CONGRESS 2017

5 - 7 OCTOBER 2017 | CITY CONVENTION CENTRE

WHO YOU WILL MEET:

Industries (including but not limited to):
- Cancer Centre
- Medical Research Institutes
- Hospitals (Public & Private & Community)
- Medical Universities
- Aged Care Providers
- Pharmaceuticals
- Biotechnological
- Biomedical Sciences
- Health Care & Medical Equipment Providers
- Government Administration, Regulators & Relations
- International Cancer Care & Health Care Associations
- Laboratory Facilities & Hospital Architecture
- Consulting Firms
- Health Care Information Technology and Services
- Insurance Sector
- Older People’s Association
- International Non-Profit Organization

In the Roles of:
Board level as well as senior management level as below would benefit from attending this congress:
- Medicine Oncology
- Clinical and Translational Cancer Research
- Haematology Oncology
- Immunology
- Tumor and Cancer Development
- Personalized Cancer Therapeutics
- Medical Biochemistry
- Cellular Therapy & Engineering Facility
- Cancer Biology
- Microbiology
- Pharmacy & Experimental Pharmacology
- Genomic Cancer Medicine
- CRISPR
- Pathology
- Palliative Care and Supportive Unit
- Geriatric & Gerontology
- Nursing
- Cancer Epidemiology
- Clinical Vaccine Research & Development

Seniority Level of Participants

Seniority Level: 80% of Participants will be Head of Departments & Above
- Board / C-Level / President / Director / MD – 20%
- VP / Director / General Manager – 20%
- Head of Departments / Chief Investigator / Group Leader / Team Leader / Laboratory Head – 40%
- Senior Staff Specialist / Manager Senior Researcher / Clinical Research Officer / Research Fellow – 20%

Call: +61 3 9909 7310 | Email: admissions@claridenglobal.com | Visit: http://www.claridenglobal.com
Congress Highlights

10 KEY BENEFITS WHEN YOU JOIN US IN OCTOBER AT THE
TARGETED ANTI-CANCER THERAPIES, IMMUNOTHERAPY
& DRUG DELIVERY WORLD CONGRESS 2017

A - cquire groundbreaking medical & clinical research findings in cancer management
N - avigate cancer care more effectively by basing on extraordinary successful medical breakthrough in recent years
T - ap into newly published scientific ideas and experimental trials that will lead to the next generation of active research projects
I - mprove survivorship rate by strengthening models of cancer care
C - urb the proliferation of cancerous cell by improving and developing novel targeted therapies
A - ccelerate coordinated attack on cancer by enhancing current clinical trial design and results of clinical trials
N - ip cancer in the bud through deeper understanding and identification of human genomes
C - apture a wide range of discussion on the scientific aspects of cancer biology all the way to patient advocacy
E - ngage and strike mutually beneficial partnerships with academic & industry practitioners in both public & private sectors
R - evolutionize cancer care with the augmentation of technology in boosting future scientific discoveries
### Main Congress Agenda

#### DAY ONE – 6 OCTOBER 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker &amp; Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Opening Address and Day 1 Highlights by Chairperson</td>
<td></td>
</tr>
<tr>
<td>09:15</td>
<td>Understanding the Biochemical Basis of Cytotoxic Mechanism of NK Cells and T Lymphocytes</td>
<td>Dr Ilia Voskoboinik, Group Leader &amp; Chief Investigator, Immunology, Biogenesis of Cytotoxic Granules Peter MacCallum Cancer Centre</td>
</tr>
<tr>
<td>09:45</td>
<td>Augmenting CAR T Cell Function for Application in Solid Cancer</td>
<td>Dr Paul A. Beavis, Chief Investigator, Immunotherapy Program Peter MacCallum Cancer Centre</td>
</tr>
<tr>
<td>10:15</td>
<td>IMMUNOTHERAPY</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>NK (Natural Killer) Cell Cancer Immunotherapies</td>
<td>Dr Nicholas Huntington, Lab Head: Molecular Immunology Division, Walter &amp; Eliza Hall Institute of Medical Research (WEHI)</td>
</tr>
<tr>
<td>11:15</td>
<td>Immunotherapy 2.0: Advancing Cancer Treatment with IDO1 Inhibitors</td>
<td>A/Prof Ching Lai-Ming, Professor and Head: Stromal Targeting Agents Group Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences University of Auckland</td>
</tr>
<tr>
<td>11:45</td>
<td>Survival Results from a Phase III Trial of Nivolumab Combined with Ipilimumab in Treatment-naïve Patients with Advanced Melanoma (CheckMate 067)</td>
<td>Dr Peter Hersey, Honorary Professor in Immuno Oncology Centenary Institute, University of Sydney</td>
</tr>
<tr>
<td>12:15</td>
<td>Gene Mutations &amp; Signaling Pathways</td>
<td>Dr Matt Dun, Group Leader: Molecular Oncology Group Hunter Medical Research Institute (HMRI)</td>
</tr>
<tr>
<td>12:45</td>
<td>Lunch &amp; Networking</td>
<td></td>
</tr>
</tbody>
</table>
Targeting the Epigenome in Acute Myeloid Leukemia (AML)

- AML is a heterogenous disease with poor prognosis and novel treatment strategies are urgently required. Epigenetic regulators are frequently mutated in AML and are attractive targets for therapy.
- We are using advanced genetic tools and in vivo mouse models to understand the role of specific genes in leukaemia initiation, maintenance and progression.
- Data will be presented on targeted therapies that are designed for AML patients that carry mutations in the epigenetic regulators IDH1/2 and DNMT3A.

Dr Lev Kats
Team Leader: Cancer Therapeutics Program
Peter MacCallum Cancer Centre

Activation of Nucleolar DNA Damage Signalling by CX-5461 is a Novel Therapeutic Strategy for High-Grade Serous Ovarian Cancer

- Inhibition of RNA Polymerase I using CX-5461 is a novel targeted therapy in ovarian cancer.
- CX-5461 shows therapeutic efficacy in combination with chemotherapy and PARP inhibitors in ovarian cancer cell lines and patient-derived cells.
- A phase II clinical trial in ovarian cancer is planned for 2018 at Peter MacCallum Cancer Centre.

Dr Elaine Sanij
Senior Scientist: Cancer Signalling Laboratory, Oncogenic Signalling and Growth Control Program
Peter MacCallum Cancer Centre
## Main Congress Agenda

### DAY TWO – 7 OCTOBER 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Congress Introduction and Day 2 Highlights by Chairperson</td>
</tr>
<tr>
<td>09:05</td>
<td>Nanotheranostics for Cancer Management</td>
</tr>
<tr>
<td></td>
<td>• The advantages and limitations of nanotheranostics in cancer management</td>
</tr>
<tr>
<td></td>
<td>• Understand how the dual functioning of nanomaterials as an efficient</td>
</tr>
<tr>
<td></td>
<td>diagnostic and therapeutic agent can help in the development of</td>
</tr>
<tr>
<td></td>
<td>personalized and highly efficacious oncology nanomedicines with</td>
</tr>
<tr>
<td></td>
<td>minimal or toxicity</td>
</tr>
<tr>
<td></td>
<td>• Case Study: Explore the potential of nanotheranostics in</td>
</tr>
<tr>
<td></td>
<td>current prostate cancer treatments</td>
</tr>
<tr>
<td></td>
<td>Dr Prashant Sawant</td>
</tr>
<tr>
<td></td>
<td>Chief Scientist</td>
</tr>
<tr>
<td></td>
<td>Intraceuticals</td>
</tr>
<tr>
<td>09:35</td>
<td>Breakthrough in using Soft Robotics Devices for Drug Delivery</td>
</tr>
<tr>
<td></td>
<td>• Explore the potential for robotic drug delivery system in cancer care</td>
</tr>
<tr>
<td></td>
<td>• Address the barriers in carrying out targeted drug delivery with</td>
</tr>
<tr>
<td></td>
<td>soft robotics</td>
</tr>
<tr>
<td>10:00</td>
<td>Exploring the Minimally Invasive Option for Cancer Treatment - Nanoknife, the Irreversible Electroporation</td>
</tr>
<tr>
<td></td>
<td>• Review the current development of Nanoknife: the targeted, non-thermal,</td>
</tr>
<tr>
<td></td>
<td>focal ablation therapy used for inoperable tumors</td>
</tr>
<tr>
<td></td>
<td>• Case Study: Findings derived from Phase I Clinical Trials with</td>
</tr>
<tr>
<td></td>
<td>Nanoknife in Prostate Cancer, Safety study in Liver Cancer, Renal</td>
</tr>
<tr>
<td></td>
<td>and Lung Cancer and clinical experience and review of recent literature in Pancreatic Cancer.</td>
</tr>
<tr>
<td></td>
<td>• What is the future of Nanoknife: wider application in other types of</td>
</tr>
<tr>
<td></td>
<td>cancer?</td>
</tr>
<tr>
<td></td>
<td>• Explore the possibility of combination therapies in cancer management:</td>
</tr>
<tr>
<td></td>
<td>Nanoknife + immunotherapy + chemotherapy + surgical therapy +</td>
</tr>
<tr>
<td></td>
<td>radiotherapy</td>
</tr>
<tr>
<td>11:00</td>
<td>Targeting Fibroblast Growth Factor Signalling Pathway in Hepatocellular Carcinoma (HCC)</td>
</tr>
<tr>
<td></td>
<td>• Fibroblast growth factor receptor (FGFR) as a promising target for</td>
</tr>
<tr>
<td></td>
<td>hepatocellular carcinoma therapy</td>
</tr>
<tr>
<td></td>
<td>• Pan-FGFR and FGFR-4 specific inhibitors in clinical development</td>
</tr>
<tr>
<td></td>
<td>• Combination therapy of FGFR inhibitors with chemotherapy</td>
</tr>
<tr>
<td></td>
<td>Dr Huynh The Hung</td>
</tr>
<tr>
<td></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td></td>
<td>Lab of Molecular Endocrinology</td>
</tr>
<tr>
<td></td>
<td>Division of Cellular &amp; Molecular Research</td>
</tr>
<tr>
<td></td>
<td>National Cancer Centre Singapore (NCCS)</td>
</tr>
<tr>
<td>11:20</td>
<td>Angiogenesis Inhibitors: Arresting the Proliferation of Cancer with Inhibitors</td>
</tr>
<tr>
<td></td>
<td>• Restraining cancer growth with Vascular Endothelial Growth Factor (VEGF) Inhibitor (Case Study)</td>
</tr>
<tr>
<td></td>
<td>• Restraining cancer growth with Epidermal Growth Factor Receptor (EGFR) Inhibitor (Case Study)</td>
</tr>
<tr>
<td>11:40</td>
<td>Exploring Intracellular Antibodies as A Novel Approach to Directly Trigger Bak-mediated Apoptosis</td>
</tr>
<tr>
<td></td>
<td>• An antibody can specifically bind the pro-apoptotic effector Bak at</td>
</tr>
<tr>
<td></td>
<td>mitochondria to trigger intrinsic apoptosis</td>
</tr>
<tr>
<td></td>
<td>• Antibody is not sequestered by pro-survival Bcl-2 proteins so may</td>
</tr>
<tr>
<td></td>
<td>bypass certain forms of resistance</td>
</tr>
<tr>
<td></td>
<td>• Antibody derivatives are being engineered for targeting and delivery</td>
</tr>
<tr>
<td></td>
<td>into cancer cells</td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch &amp; Networking</td>
</tr>
<tr>
<td>13:00</td>
<td>Hormone Therapies: Reducing Recurrence and Increasing Survival in Prostate and Breast Cancer</td>
</tr>
<tr>
<td></td>
<td>• A look at synthetic and nature forms of hormone treatment</td>
</tr>
<tr>
<td></td>
<td>• Revising the study on the effects of adding testosterone pellets into</td>
</tr>
<tr>
<td></td>
<td>women through hormone replacement therapy</td>
</tr>
<tr>
<td></td>
<td>• Determining the best treatment: hormone therapies, prostatectomy,</td>
</tr>
<tr>
<td></td>
<td>mastectomy</td>
</tr>
</tbody>
</table>

**Call:** +61 3 9909 7310 | **Email:** admissions@claridenglobal.com | **Visit:** http://www.claridenglobal.com
13:30  Tumour Vaccinology: Reinforcing the Body with Highly Potent Vaccines
- Discover the latest development in tumour vaccines through a deep review on peptide molecules
- Explore the usage of vaccine in neoadjuvant and adjuvant therapy
- How does the combination of computer-aided drug discovery and cutting edge screening technologies aid in the development of tumour vaccinology

14:00  CRISPR: Killing Cancer Cells with Genome Editing
- Discover the potential of gene-editing technology (CRISPR-Cas-9) in the battle against cancer
- Explore the usage of CRISPR as a gene screening tool to identify novel drug targets for cancer therapy
- Discuss the associated risk of using CRISPR in decoding genome and developing cancer resistant human genome

Dr Tan Meng How
Senior Research Scientist of Stem Cell & Regenerative Biology
Genome Institute of Singapore (GIS)
Assistant Professor, School of Chemical and Biomedical Engineering, College of Engineering
Nanyang Technological University, Singapore

14:30  Stem Cell Therapy: The Revolutionary & Regenerative Treatment for Cancer
- Case Study: A Tissue Engineered Humanised Bone to Study Cancer Metastasis In Vivo
- We could develop a morphologically and functionally intact human bone organ which contained human extracellular matrix components. The bone organ was further humanised through the injection of human cord blood derived haematopoietic stem cells (HSC) which populated in the mouse BM and hTE-BM niche and stimulated human haematopoiesis within the murine host in a time- and dose-dependent manner.
- Of interest, metastatic cancer cells injection resulted in the formation of a primary tumour and spontaneous metastasis to the hTE-BM.
- Less frequent metastasis and lower tumour burden were observed in mice with a humanised immune system, suggesting immune-mediated response against the cancer cells.
- Potential development of new therapeutics against bone metastasis

Dr Abbas Shafiee
Postdoctoral Research Fellow, Institute of Health and Biomedical Innovation
Queensland University of Technology

15:00  Afternoon Refreshments and Networking

15:30  Integrative Oncology
- The use of complementary therapies in combination with conventional medicine
- How to support a cancer patient and further stimulate their immune system

Vanita Dahlia
Integrative Medicine Practitioner, Functional Pathology Clinical Consultant & Chief Educator
NutriPath

16:00  Endocrine Disruptors and Environmental Toxicants in Cancer
- The role of estrogens and toxicants in cancer proliferation
- Unpacking specific markers in Functional pathology and genetics revealing the impact of toxicants, endocrine disruptors and hormone metabolism in patients diagnosed with cancer
- How to read, interpret and treat a patient
- Nutrient therapies tailored to specific lab results and advances in the latest nutrient based targeted therapies.
- Avenues of further investigation in cancer and how it can affect other organ systems

Dr Abbas Shafiee
Postdoctoral Research Fellow, Institute of Health and Biomedical Innovation
Queensland University of Technology

16:30  Closing Remarks by Congress Chairperson
- The role of estrogens and toxicants in cancer proliferation
- Unpacking specific markers in Functional pathology and genetics revealing the impact of toxicants, endocrine disruptors and hormone metabolism in patients diagnosed with cancer
- How to read, interpret and treat a patient
- Nutrient therapies tailored to specific lab results and advances in the latest nutrient based targeted therapies.
- Avenues of further investigation in cancer and how it can affect other organ systems
Providing integrated care to cancer survivors is becoming a global challenge for policymakers, employers and health care professionals as more and more people live with and beyond cancer. The need for care pathways that map treatment, rehabilitation and aftercare (survivorship plans) from start to finish is greatly warranted. Due to the terrifying power of cancer, the changing prognosis of a cancer patient put incredible stress on family and carers. At one time, they can be prepared for a family member to die and another, it turns out the family member survives. Even though standard of cancer care is very high in Australia with detailed cancer plans that encompass the whole journey from diagnosis through treatment and supportive care to survivorship management and palliative care, there is still a significant gap in the level of support to cancer survivors. Therefore, this workshop is designed to help you to

- Establish seamless care pathways that map treatment, rehabilitation and after care for cancer survivors
- Break down silos in improving the integration and continuity of care for cancer patients
- Manage emotions, stress, anger, anxiety and depression of cancer patients and their carers
- Provide psychological strategies in managing cancer survivors

Site Visit: 13:00 – 16:30

Advocating Personalised Medicine with Palliative Care

- Engage in meaningful conversations about life, sickness and death
- Encourage patients to discuss dying wishes
Make the most of
Targeted Anti-Cancer Therapies, Immunotherapy & Drug Delivery World Congress 2017

5 - 7 October 2017 | City Convention Centre

Media Partners

HOSPITAL + HEALTH

Connecting Medical Suppliers with Key Healthcare personnel and decision makers throughout Australia for the past 41 years. Looking for a product or service? Go to www.hospitalsuppliers.com.au

DermNet New Zealand

DermNet NZ is the most popular website worldwide for patients and health professionals seeking information about skin diseases. We are a charitable organisation run by a community of expert dermatologists and other health specialists. Our mission is to make authoritative information about the skin accessible to anyone in the world with an internet connection. For more information, please visit http://www.dermnetnz.org/

Capitalise on this Congress

Do you have solutions to assist and contribute to the overall improvement of the oncology industry? Looking for the ideal platform to raise your profile and to increase your ROI?

Leverage our limited sponsorship packages to strengthen and confirm your market position through consistent and continual branding awareness and take advantage of the plethora of opportunities with high level decision makers.

Your Partnership with us will provide you with:

• Unparalleled industry exposure
• Leads generation and set-up of meetings with key decision makers
• Positioning your company as a thought-leader
• Reaffirming your position in the industry

Please contact Audrey at +65 6716 9986 or email audrey@claridenglobal.com to discuss potential exhibition and sponsorship opportunities or to customize your own package.

Benefits as Media Partner or Supporting Organization at Targeted Anti-Cancer Therapies, Immunotherapy & Drug Delivery World Congress 2017

• Enhance your corporate profile and visibility within your industry – Your company’s logo will be emblazoned on our brochures and distributed to the professionals in the oncology industry across Australia
• Affiliation with an internationally recognized commercial event organizer

Clariden Global events are widely known and trusted internationally for giving best value to senior industry executives. We partner with selected media and supporting organizations, capable of delivering the highest caliber of expert knowledge and key industry insights to the target market.

If you meet the criteria mentioned above and would like to explore the opportunity to partner with us for Targeted Anti-Cancer Therapies, Immunotherapy & Drug Delivery World Congress 2017, please contact Stefanie at +44 (0)20 7129 1222 or email stefanie@claridenglobal.org
Please complete this section.

Booking Contact (Approving Manager) Mr/Mrs/Ms: ____________________________
Job Title: ____________________________ Department: ____________________________
Telephone: ____________________________ Fax: ____________________________
Email: ____________________________ Address: ____________________________ Postal Code: _________________

I would like to receive more information on hotel accommodation using Clariden Global corporate rate.

Promotional Code (Optional): ____________________________________________

Please register the following participant(s) for this Summit
(Please tick to select your Congress packages. You may tick more than one.)

1st Participant Name (Mr/Mrs/Ms): ____________________________________________
Job Title: ____________________________ Department: ____________________________
Telephone: ____________________________ Fax: ____________________________
Email: ____________________________ Date of Birth: ____________________________
Congress Package Selected: ____________________________________________

2nd Participant Name (Mr/Mrs/Ms): ____________________________________________
Job Title: ____________________________ Department: ____________________________
Telephone: ____________________________ Fax: ____________________________
Email: ____________________________ Date of Birth: ____________________________
Congress Package Selected: ____________________________________________

3rd Participant Name (Mr/Mrs/Ms): ____________________________________________
Job Title: ____________________________ Department: ____________________________
Telephone: ____________________________ Fax: ____________________________
Email: ____________________________ Date of Birth: ____________________________
Congress Package Selected: ____________________________________________

4th Participant Name (Mr/Mrs/Ms): ____________________________________________
Job Title: ____________________________ Department: ____________________________
Telephone: ____________________________ Fax: ____________________________
Email: ____________________________ Date of Birth: ____________________________
Congress Package Selected: ____________________________________________

CONGRESS FEES

<table>
<thead>
<tr>
<th>Congress Packages</th>
<th>Super Early Bird Fee</th>
<th>Early Bird Fee</th>
<th>Final Early Bird Fee</th>
<th>Regular Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>A: 2-day Congress Only</td>
<td>AU$1,595</td>
<td>AU$1,795</td>
<td>AU$1,895</td>
<td>AU$1,995</td>
</tr>
<tr>
<td>B: 2-Day Congress &amp; Workshop</td>
<td>AU$1,995</td>
<td>AU$2,195</td>
<td>AU$2,395</td>
<td>AU$2,595</td>
</tr>
<tr>
<td>C: 2-Day Congress &amp; Site Visit &amp; Workshop <em>Most Value</em></td>
<td>AU$2,195</td>
<td>AU$2,395</td>
<td>AU$2,495</td>
<td>AU$2,595</td>
</tr>
<tr>
<td>D: 2-day Congress Only *Most Popular Option!</td>
<td>AU$995</td>
<td>AU$1,095</td>
<td>AU$1,195</td>
<td>AU$1,295</td>
</tr>
<tr>
<td>E: 2-Day Congress &amp; Workshop</td>
<td>AU$1,995</td>
<td>AU$1,495</td>
<td>AU$1,595</td>
<td>AU$1,695</td>
</tr>
<tr>
<td>F: 2-Day Congress &amp; Site Visit &amp; Workshop <em>Most Value</em></td>
<td>AU$1,495</td>
<td>AU$1,695</td>
<td>AU$1,795</td>
<td>AU$1,895</td>
</tr>
</tbody>
</table>

For Government, Hospitals, Clinics, Biotech Professionals, Pharmaceuticals:

Please NOTE: The congress fee includes lunch, refreshments and conference documentation. Payments are required with registration and must be received prior to the congress to guarantee your place.

GROUP DISCOUNTS

Register with your Colleagues Today to Enjoy Group Discount*: Group discount of 10% for the 2nd participant from the same organization.
For limited time only by 7 September 2017, register 3 participants and the 4th participant will receive a complimentary seat.
For 5 or more registrations, please contact Stefanie at stefanie@claridenglobal.org

*C Only 1 discount scheme will apply. Discount will only be applicable to the package of the lowest value. Discount will compound on top of your early bird discount!

4 WAYS TO REGISTER

Email: admissions@claridenglobal.com
Fax: +61 3 9909 7788
Call: +61 3 9909 7310
Website: www.claridenglobal.com

PAYMENT METHODS

BY CHEQUE / BANK DRAFT:
Made payable to CLARIDEN GLOBAL INTERNATIONAL LIMITED and mail to: 3 International Business Park, #04-29, Nordic European Centre, Singapore 609927.

BY TELEGRAPHIC TRANSFER TO:
Bank Name: Standard Chartered Bank
Bank Code: 7144
Bank Branch Code: 001
Bank Address: 6 Battery Road, #01-01 Singapore 049909
Bank Account No: 0107775042
Bank Account Name: CLARIDEN GLOBAL INTERNATIONAL LIMITED
SWIFT Code: SCBLSG22

Please note that all bank charges are to be borne by participants. Please ensure Clariden Global International Limited receives the full invoiced amount.

Note: Please include invoice number on all payment types and your company’s name in your payment instructions for our reference.

CREDIT CARD:
To make payment by credit card, please call our client services hotline at +61 3 9909 7310.

CONFERENCE VENUE AND ACCOMMODATION INFORMATION

City Convention Centre
5 – 7 October 2017
Level 12, 300 Flinders St, Melbourne VIC 3000, Australia
Tel: +61 3 9919 1326
Website: https://www.vu.edu.au/convention-centres/city-convention-centre

HOW TO REGISTER AND PAY

An invoice and registration confirmation will be sent within 7 days, please contact us if you have not heard from us within 7 days. Payment can be made by credit card, by bank transfer or by cheque made payable to “CLARIDEN GLOBAL INTERNATIONAL LIMITED”.

ALL PAYMENTS MUST BE RECEIVED IN ADVANCE OF THE EVENT.

ACCOMMODATION

Accommodation is not included in the program fee but you will be entitled to use our corporate rate for your accommodation. Information will be sent along with your registration confirmation.

CANCELLATIONS AND SUBSTITUTIONS

Once we have received your booking, the place(s) are confirmed. No refunds will be made for any cancellations, however, program credits of equivalent value only applicable for Clariden Global events will be provided. Credits can only be redeemed for one program and is valid for only one (1) year from date of issue.
Substitution with a qualified candidate is allowed by providing at least 5 working days notice of substitution. Subsequent substitutions will be charged 10% admin fee.

ALL CANCELLATIONS MUST BE RECEIVED IN WRITTEN FORM

PLEASE NOTE: CLARIDEN GLOBAL INTERNATIONAL LIMITED reserves the right to change the content and timing of the programme, the speakers and the date and venue due to reasons beyond our control. If in the unlikely event that the course is cancelled, CLARIDEN GLOBAL INTERNATIONAL LIMITED will refund the full amount and disclaim any further liability.

ENQUIRIES: If you have any queries about registration or payment please do not hesitate to contact our client services department on +61 3 9909 7310.

PRIVATE DISCLOSURE STATEMENT: Any information provided by you in relation to this event is being collected by CLARIDEN GLOBAL INTERNATIONAL LIMITED and will be held in the strictest confidence. It will be added to our database for the primary purpose of providing you with information about future events and services.

Visit us at www.claridenglobal.com for upcoming events

FOR OFFICIAL USE

FEE RECEIVED | REFERENCE L7251/50-ST